Lung Cancer
Volume 72, Issue 1 , Pages 84-91 , April 2011

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

  • Fernanda Salazar

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Miguel Angel Molina

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Maria Sanchez-Ronco

      Affiliations

    • University of Alcala de Henares, Madrid, Spain
    • ,
  • Teresa Moran

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Jose Luis Ramirez

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Jose Miguel Sanchez

      Affiliations

    • Hospital Doce de Octubre, Madrid, Spain
    • ,
  • Rolf Stahel

      Affiliations

    • Universitatsspital, Zurich, Switzerland
    • ,
  • Pilar Garrido

      Affiliations

    • Ramon y Cajal, Madrid, Spain
    • ,
  • Manuel Cobo

      Affiliations

    • Hospital Carlos Haya, Malaga, Spain
    • ,
  • Dolores Isla

      Affiliations

    • Hospital Lozano Blesa, Zaragoza, Spain
    • ,
  • Jordi Bertran-Alamillo

      Affiliations

    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Bartomeu Massuti

      Affiliations

    • Hospital General de Alicante, Alicante, Spain
    • ,
  • Felipe Cardenal

      Affiliations

    • Catalan Institute of Oncology, Hospitalet, Spain
    • ,
  • Christian Manegold

      Affiliations

    • Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany
    • ,
  • Pilar Lianes

      Affiliations

    • Hospital de Mataro, Mataro, Spain
    • ,
  • Jose Manuel Trigo

      Affiliations

    • Hospital Virgen de la Victoria, Malaga, Spain
    • ,
  • Jose Javier Sanchez

      Affiliations

    • Autonomous University of Madrid, Madrid, Spain
    • ,
  • Miquel Taron

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Rafael Rosell

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • Corresponding Author InformationCorresponding author at: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain. Tel.: +34 93 497 89 25; fax: +34 93 497 89 50.

Received 17 May 2010 ,Accepted 11 July 2010.

References 

  1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550
  3. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20:4285–4291
  4. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group – EORTC 08975. J Clin Oncol. 2003;21:3909–3917
  5. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016–3024
  6. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  7. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–1537
  8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  9. Weiss G, Rosell R, Fossella F, Perry M, Stahel R, Barata F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18:453–460
  10. Itaya T, Yamaoto N, Ando M, Ebisawa M, Nakamura Y, Murakami H, et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 2007;98:226–230
  11. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest. 1994;94:703–708
  12. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol. 2007;25:2747–2754
  13. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem. 1998;273:23419–23425
  14. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene. 2002;21:8723–8731
  15. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 2006;25:7381–7390
  16. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029–1040
  17. Bache KG, Slagsvold T, Stenmark H. Defective downregulation of receptor tyrosine kinases in cancer. EMBO J. 2004;23:2707–2712
  18. Chaturvedi P, Sudakin V, Bobiak ML, Fisher PW, Mattern MR, Jablonski SA, et al. CHFR regulates a mitotic stress pathway through its RING-finger domain with ubiquitin ligase activity. Cancer Res. 2002;62:1797–1801
  19. Scolnick DM, Halazonetis TD. CHFR defines a mitotic stress checkpoint that delays entry into metaphase. Nature. 2000;406:430–435
  20. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999;286:309–312
  21. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, et al. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene. 2002;21:2328–2333
  22. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–9826
  23. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11:5878–5885
  24. Moran T, Paz-Ares L, Isla D, Cobo M, Massuti B, Insa A, et al. High correspondence between EGFR mutations in tissue and in circulating DNA from non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). ASCO Annu Meet: J Clin Oncol. 2007;
  25. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55
  26. Van Schaeybroeck S, Kyula J, Kelly DM, Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, et al. Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells. Mol Cancer Ther. 2006;5:1154–1165
  27. Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818
  28. Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744–752
  29. Lee DH, Park K, Kim JH, Lee JS, Shin SW, Kang JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res. 2010;16:1307–1314
  30. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene. 2007;26:3431–3439
  31. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zhang D, Merkle CJ, et al. CHFR is required for tumor suppression and Aurora A regulation. Nat Genet. 2005;37:401–406
  32. Kang D, Chen J, Wong J, Fang G. The checkpoint protein CHFR is a ligase that ubiquitinates Plk1 and inhibits Cdc2 at the G2 to M transition. J Cell Biol. 2002;156:249–259
  33. Yang S, Qu S, Perez-Tores M, Sawai A, Solit DB, Rosen N, et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 2006;66:6990–6997
  34. Ramirez JL, Sarries C, de Castro PL, Roig B, Queralt C, Escuin D, et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 2003;193:207–216
  35. Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Penas R, et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: the Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105–9112

PII: S0169-5002(10)00368-5

doi: 10.1016/j.lungcan.2010.07.008

Lung Cancer
Volume 72, Issue 1 , Pages 84-91 , April 2011

Article Tools

* Image Usage & Resolution